Skip to content

Study · Non-randomized trial · n = 30 · 2018

2 results

Changes of Circulating MicroRNAs in Response to Treatment With Teriparatide or Denosumab in Postmenopausal Osteoporosis.

Anastasilakis AD, Makras P, Pikilidou M, Tournis S, Makris K, Bisbinas I, Tsave O, Yovos JG, Yavropoulou MP

The Journal of clinical endocrinology and metabolism1 Mar 2018Cited by 49 (Europe PMC)

PMID29309589 (opens in a new tab)DOI10.1210/jc.2017-02406 (opens in a new tab)PepBankPUB-29309589
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialMechanism

    In postmenopausal women with low bone mass, serum miR-33-3p expression decreased during teriparatide treatment.

    In plain wordsIn women with low bone mass, serum miR-33-3p decreased during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseSerum miR-33-3p expression
    Study

    n = 30

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    We found significantly decreased relative expression of miR-33-3p at 3 months (P = 0.03) and of miR-133a at 12 months (P = 0.042) of TPTD treatment.
    2 context sentences
    Summary · context
    Observational, open label, nonrandomized clinical trial.
    Summary · context
    Postmenopausal women with low bone mass were treated with either teriparatide (TPTD; n = 30) or denosumab (n = 30) for 12 months.
  2. 02HumanNon-randomized trialMechanism

    In postmenopausal women with low bone mass, serum miR-133a expression decreased during teriparatide treatment.

    In plain wordsIn women with low bone mass, serum miR-133a decreased during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseSerum miR-133a expression
    Study

    n = 30

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    We found significantly decreased relative expression of miR-33-3p at 3 months (P = 0.03) and of miR-133a at 12 months (P = 0.042) of TPTD treatment.
    2 context sentences
    Summary · context
    Observational, open label, nonrandomized clinical trial.
    Summary · context
    Postmenopausal women with low bone mass were treated with either teriparatide (TPTD; n = 30) or denosumab (n = 30) for 12 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.